Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. Show more

535 W 24th Street, New York, NY, 10011, United States

Biotechnology

Healthcare

Market Cap

497M

52 Wk Range

$15.93 - $37.27

Previous Close

$31.45

Open

$31.89

Volume

680,099

Day Range

$31.43 - $34.35

Enterprise Value

261M

Cash

243.2M

Avg Qtr Burn

-26.12M

Insider Ownership

8.83%

Institutional Own.

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NGN-401 Details Rett syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NGN-101 Details Rare genetic disease, Batten Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.